

OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person * <u>Basho Chandan</u> _____ (Last) (First) (Middle) 1668 S. GARFIELD AVENUE 2ND FLOOR _____ (Street) ALHAMBRA CA 91801 _____ (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Apollo Medical Holdings, Inc. [ AMEH ]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner Officer (give title below) Other (specify below) X See Remarks
	3. Date of Earliest Transaction (Month/Day/Year) 05/16/2023	
		4. If Amendment, Date of Original Filed (Month/Day/Year) 05/25/2023

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	05/16/2023		D		48,086 <sup>(1)</sup>	D	\$0	26,359	D	
Common Stock	05/16/2023		A		9,121 <sup>(2)(5)</sup>	A	\$0	35,480	D	
Common Stock	05/16/2023		A		60,808 <sup>(3)(5)</sup>	A	\$0	96,288	D	
Common Stock	05/16/2023		A		60,803 <sup>(4)(5)</sup>	A	\$0	157,091 <sup>(6)</sup>	D	

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V		(A)	(D)					

**Explanation of Responses:**

- Represents cancellation of previously-granted performance-based restricted stock award. The original Form 4 filed on May 25, 2023 inadvertently omitted this cancellation. Total holdings in column 5 have been adjusted accordingly, including for previously-reported tax withholdings.
- Represents restricted shares of the Issuer's common stock granted pursuant to the Issuer's 2015 Equity Incentive Plan. Provided the Reporting Person is still employed with the Issuer on the date of vesting, the shares shall vest in two equal (as nearly as possible) annual installments beginning on May 16, 2024.
- Represents restricted shares of the Issuer's common stock granted pursuant to the Issuer's 2015 Equity Incentive Plan. Provided the Reporting Person is still employed with the Issuer on the date of vesting, the shares shall vest in four equal (as nearly as possible) annual installments, beginning on May 16, 2024.
- Represents restricted shares of the Issuer's common stock granted pursuant to the Issuer's 2015 Equity Incentive Plan. Provided the Reporting Person is still employed with the Issuer on the date of vesting, the shares shall vest upon achievement of certain pre-established performance goals.
- These grants were previously reported in the aggregate in the original Form 4 filed on May 25, 2023.
- Includes 152,372 shares of restricted stock, which will vest as follows (in each case subject to continuous employment with the Issuer): (i) 21,640 shares, which vest in three equal annual installments on April 14, 2024, 2025, and 2026; (ii) 9,121 shares, which vest in two equal annual installments on May 16, 2024 and 2025; (iii) 60,808 shares, which vest in four equal annual installments on May 16, 2024, 2025, 2026 and 2027; and (iv) 60,803 shares, which vest upon achievement of certain pre-established performance goals.

**Remarks:**

Chief Financial Officer and Chief Strategy Officer

/s/ Chandan Basho

10/17/2023

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.